Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Fallopian Tube Cancer: early-phase trial registry
1 of 6 indexed Recurrent Fallopian Tube Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Recurrent Fallopian Tube Cancer: 6 US clinical trials tracked, 1 recruiting.
Recurrent Fallopian Tube Cancer is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is University of Chicago, running 2 of these trials.
Enrollment posture brief
Registry condition recurrent-fallopian-tube-cancer
OPEN 1 | RECR 17% | LATE 0 | EARLY 6 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
Recurrent Fallopian Tube Cancer lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Fallopian Tube Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Fallopian Tube Cancer is recruiting below its size-band peers.
1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Fallopian Tube Cancer research.
University of Chicago accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Fallopian Tube Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 74 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.
-
Recurrent Fallopian Tube Cancer research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
NCT03564340
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
NCT02122185
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio
NCT05335993
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
National Cancer Institute (NCI)
NCT00278343
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
NCT02046421
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
Case Comprehensive Cancer Center
NCT01652794
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Fallopian Tube Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Fallopian Tube Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Fallopian Tube Cancer page
6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Fallopian Tube Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Chicago sponsors the most Recurrent Fallopian Tube Cancer trials on record, review their full trial history before evaluating a specific study. See University of Chicago's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Fallopian Tube Cancer condition card totals 6 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.